[Cirrhotic portal hypertension in the non-invasive era: what we grasp]

The non-invasive era of portal hypertension in cirrhosis is approaching. We should seize the opportunity: then do learn to follow the recommended international guidelines for emerging non-invasive technologies and systematically utilize case resources of our country's for clinical verification; Secondly, we should pay attention to the cross-theory innovation of the middle level discipline in the process of technology development, and standardize the design and clinical registration in accordance with international diagnostic testing standards; Finally, a non-invasive technique for the treatment of cirrhotic portal hypertension was developed with a developmental perspective, enabling the transition from disease diagnosis and risk stratification to efficacy monitoring and prognosis prediction.

Progress in research of IL-10 and IL-17 in chronic hepatitis B, hepatitis B virus-related liver cirrhosis and cirrhosis with abdominal infection

Hepatitis B is a global contagious disease, posing a serious threat to human health. However, its pathogenic mechanisms and how it ultimately leads to the formation of cirrhosis are not fully understood. Elucidating the progression of hepatitis B and the mechanism responsible for liver cirrhosis formation can help develop novel antiviral treatment and anti-fibrosis therapy. In recent years, great progress has been made in understanding the pathogenesis of chronic hepatitis and liver cirrhosis and their treatment. Cytokines have become a research hotspot in this field. Emerging evidence suggests that a variety of cytokines in the liver have a quite significant role in the progressive process of HBV. Cytokines mainly mediate cell-cell interactions in paracrine, feedback or other manners to participate in the pathogenesis of chronic hepatitis B, cirrhosis and cirrhosis with infection. In recent years, many studies suggest that serum interleukin-10 (IL-10) and IL-17 levels are correlated with the development and prognosis of chronic hepatitis B, liver cirrhosis and cirrhosis with infection. In this paper, we review the progress in research of IL-10 and IL-17 in chronic hepatitis B, liver cirrhosis and cirrhosis with infection.